Literature DB >> 2174690

Regulation of acetylcholine receptor desensitization in mouse myotubes by cytosolic cyclic AMP.

A Giovannelli1, D Farini, M C Gauzzi, S Alema, F Eusebi.   

Abstract

Whole-cell currents activated by bath applications of acetylcholine (ACh) (10-30 microM) were recorded from patch-clamped myotubes of the mouse C2 cell line. Increasing concentrations of forskolin caused a dose-dependent fast decay of ACh-activated currents as compared to the long-lasting ACh-currents in control cells. The forskolin-induced modulation of nicotinic ACh receptor (nAChR) desensitization was proportional to the drug-induced elevation in the cyclic AMP (cAMP) cellular content. Furthermore, an increase in the rate of decay of the ACh-current response, which paralleled an elevation in cAMP cellular content, was caused by treatment with a calcitonin gene-related peptide (1 microM), 8-Br-cAMP (0.5 mM), or by loading the myotubes with cAMP. These results therefore indicate that the desensitization of nAChR is a cAMP-related process in C2-myotubes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174690     DOI: 10.1016/0898-6568(90)90064-h

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  3 in total

1.  Interleukin-2 lengthens extrajunctional acetylcholine receptor channel open time in mammalian muscle cells.

Authors:  P Lorenzon; F Ruzzier; C G Caratsch; A Giovannelli; F Velotti; A Santoni; F Eusebi
Journal:  Pflugers Arch       Date:  1991-10       Impact factor: 3.657

2.  Acetylcholine induces voltage-independent increase of cytosolic calcium in mouse myotubes.

Authors:  A Giovannelli; F Grassi; E Mattei; A M Mileo; F Eusebi; A Giovanelli
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

3.  Plasma from patients with seronegative myasthenia gravis inhibit nAChR responses in the TE671/RD cell line.

Authors:  R Barrett-Jolley; N Byrne; A Vincent; J Newsom-Davis
Journal:  Pflugers Arch       Date:  1994-10       Impact factor: 3.657

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.